TW200720254A - Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent - Google Patents
Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agentInfo
- Publication number
- TW200720254A TW200720254A TW095111919A TW95111919A TW200720254A TW 200720254 A TW200720254 A TW 200720254A TW 095111919 A TW095111919 A TW 095111919A TW 95111919 A TW95111919 A TW 95111919A TW 200720254 A TW200720254 A TW 200720254A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- hydrogen atom
- malignant tumor
- substituents
- halo
- Prior art date
Links
- JXHKUYQCEJILEI-UHFFFAOYSA-N 3,5-diphenyl-1h-pyrazole Chemical class C=1C(C=2C=CC=CC=2)=NNC=1C1=CC=CC=C1 JXHKUYQCEJILEI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It is desired to develop an anti-tumor agent having excellent anti-tumor effect for malignant tumor. This invention provides a 3,5-diphenyl pyrazole derivative or pharmaceutically acceptable salts thereof, represented by following formula (1) as effective ingredient in a proliferative inhibiting agent for malignant tumor. To provided a 3,5-diphenyl pyrazole derivative or physiologically acceptable salts, [in formula, group A represents a hydrogen atom, carbonyl or sulfonyl (tautomers are included when group A is a hydrogen atom); group J represents a lower alkyl optionally having substituents, or amino optionally having substituents; group G and Z each independently represent a hydrogen atom, hydroxyl, lower alkoxy, halo, or acyloxy optionally having substituents (provided one of group G and Z is a hydrogen atom or halo, or one of group G and Z is a hydrogen atom, another one is not a halo), group D, E, L, Q, X and Y each independently represent a hydrogen atom, amino-carbonyl optionally having substituents, lower alkoxy-carbonyl, carboxyl, nitryl, nitro, halo, lower alkyl, halo substituted-lower alkyl, lower alkoxy, lower alkylthio, lower alkyl-sulfoxyl, lower alkyl-sulfone, or amino-sulfonyl optionally having substituents; both group D and group L and/or both group Q and group Y may be together with atoms (up to 2) independently selected from nitrogen atom, oxygen atom or sulfur atom to form a hetero ring having a 5- to 6-membered ring], as effective ingredient for inhibiting method of proliferation for malignant tumor, proliferative inhibition agent for malignant tumor, especially a method for malignant tumor shrinkage and shrinkage agent for malignant tumor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005110717 | 2005-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200720254A true TW200720254A (en) | 2007-06-01 |
Family
ID=37086955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095111919A TW200720254A (en) | 2005-04-07 | 2006-04-04 | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW200720254A (en) |
| WO (1) | WO2006109680A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007040243A1 (en) * | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17beta-hydroxysteriod dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| WO2010000372A2 (en) * | 2008-06-09 | 2010-01-07 | Ludwig-Maximilians-Universität München | New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| US9493439B1 (en) * | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
| CN109748873B (en) * | 2017-11-08 | 2021-02-02 | 北京嘉林药业股份有限公司 | Compounds and their use in the treatment of cancer |
| CN110437220B (en) * | 2018-07-13 | 2022-12-27 | 暨南大学 | Triazole compound and application thereof |
| WO2021035031A1 (en) * | 2019-08-21 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3903993A1 (en) * | 1989-02-10 | 1990-08-16 | Basf Ag | DIARYL SUBSTITUTED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND MEDICINAL PRODUCTS THEREOF |
| ATE355279T1 (en) * | 1998-08-07 | 2006-03-15 | Novartis Vaccines & Diagnostic | PYRAZOLES AS MODULATORS OF THE ESTROGEN RECEPTOR |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| EP1398029A1 (en) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US20050113423A1 (en) * | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| CA2574147A1 (en) * | 2004-07-22 | 2006-02-09 | Linda Brockunier | Substituted pyrazoles, compositions containing such compounds and methods of use |
-
2006
- 2006-04-04 TW TW095111919A patent/TW200720254A/en unknown
- 2006-04-06 WO PCT/JP2006/307346 patent/WO2006109680A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006109680A1 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021086833A8 (en) | Small molecule inhibitors of kras g12c mutant | |
| TN2022000039A1 (en) | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors | |
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| ATE443063T1 (en) | A1,2,4ÜTRIAZOLOÄ4,3-AÜPYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
| UA94571C2 (en) | 3-arylamino pyridine derivatives | |
| SG132676A1 (en) | 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors | |
| MXPA05013349A (en) | 2-aminopyrimidine derivatives as raf kinase inhibitors. | |
| MXPA05012466A (en) | Quinoline derivatives as phosphodiesterase inhibitors. | |
| BG105666A (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex | |
| TNSN08227A1 (en) | [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases. | |
| TW200700397A (en) | Novel hsp90 inhibitor | |
| MXPA06013164A (en) | Pyrimidines derivatives for the treatment of abnormal cell growth. | |
| TW200504061A (en) | Pyrazolopyridine derivatives | |
| TW200642683A (en) | Heterocyclic compound | |
| MX2012001420A (en) | Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors. | |
| MY140841A (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| TW200602319A (en) | Indole derivative and use thereof | |
| BRPI0514925A (en) | pyrrol [2,3-c] pyridine derivatives and processes for preparing these | |
| JO2413B1 (en) | Benzoxazine Derivatives And Uses Thereof | |
| IL136558A0 (en) | Heterocyclic cytotoxic agents | |
| WO2008153042A1 (en) | Anti-tumor agent | |
| MX2009003728A (en) | New isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities. | |
| PT1784402E (en) | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | |
| ZA200703275B (en) | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury | |
| TW200738697A (en) | Benzimidazole derivatives as 5-HT6,5-HT24 |